Form 8-K - Current report:
SEC Accession No. 0001193125-25-265799
Filing Date
2025-11-05
Accepted
2025-11-05 08:00:33
Documents
12
Period of Report
2025-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vera-20251105.htm   iXBRL 8-K 54199
2 EX-99.1 vera-ex99_1.htm EX-99.1 199027
3 GRAPHIC img47757703_0.jpg GRAPHIC 265803
  Complete submission text file 0001193125-25-265799.txt   721760

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vera-20251105.xsd EX-101.SCH 25971
14 EXTRACTED XBRL INSTANCE DOCUMENT vera-20251105_htm.xml XML 4723
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40407 | Film No.: 251451854
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)